Abstract:Background CD4+CD25+Foxp3+ T regulatory (Treg) cells play a key role in peripheral tolerance. Rapamycin was approved by the FDA to preserve renal allografts and to be efficacious in patients with several autoimmune diseases [1]. Objectives To investigate the status of Treg cells in active refractory rheumatoid arthritis (RA) and the effects of rapamycin on patients with RA. Methods Forty-five active refractory RA patients were enrolled. Rapamycin was used at a dose of 0.5 mg every 2 days [the preliminary, open-label clinical trial of rapamycin (Clinical Trials.gov number: ChiCTR-IPR-17010307)]. Clinical improvement and immunological assessments were performed before 1st rapamycin dose and 12 weeks post treatment. Blood samples were obtained from RA patients and 75 healthy volunteers for estimation of CD4+ T cell subsets. Results Two patients dropped out due to non-compliance. As compared to healthy controls (median of Treg cells: 33.32 cell/ul), the absolute counts of circulating Treg cells were significantly decreased in patients with active refractory RA (median: 27.17 cell/ul; P=0.046). While the median ratios of Th17/Treg cells in patients with active refractory RA (median: 0.26) were significantly higher than those of healthy volunteers (median: 0.19; P=0.029). No difference in the absolute counts of circulating Th17 cells and Th1 cells was observed between patients with active refractory RA and healthy subjects. Rapamycin treatment led to clinical improvement with the median post-treatment DAS28-ESR decreasing when compared to baseline (from 4.19 to 3.78) in active refractory RA patients. Sixteen patients (16/43 patients, 37.21%) achieved an EULAR moderate response and 6 patients (6/43 patients, 13.95%) reached good response at week 12. Rapamycin administration resulted in an increase in the absolute counts of Treg cells in active refractory RA patients, from a median of 27.17 cell/ul (at week 0) to 37.57 cell/ul (at week 12) (P=0.041). The ratios of Th17/Treg cells shows a reduction from a median of 0.26 at baseline to 0.20 at week 12, but the difference is not significant (P =0.376). No significant difference was observed in the absolute counts of circulating Th17 and Th1 cells after rapamycin treatment. Interestingly, we observed that Treg cells increased before the complete remission of the disease (DAS28 score <2.6) in patients with active refractory RA. At week 12, the mean dose of prednisone which refractory RA patients were receiving decreased from 11.98 mg/d to 8.31 mg/d, with a dose reduced by ≥30% than that at baseline. The categories of DMARDs use were also reduced (P<0.05). No serious adverse events was observed during the 12-week period of rapamycin treatment. Conclusions Reduced absolute number of Treg cells was found in the patients with active refractory RA, indicating an imbalance between Th17 and Treg cells. Rapamycin elicits rapid improvement of disease activity via restoring circulating Treg cells numbers in patients with active refractory RA. References Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016. 12(3): 169–82. Disclosure of Interest None declared

Rapamycin Promotes Expansion of Cd4+Cd25+Foxp3+Regulatory T Cells by Modulating Fatty Acid Metabolism?

AB0421 Rapamycin Reduces Disease Activity Through Restoring Regulatory T Cell Numbers in Patients with Active Refractory Rheumatoid Arthritis

AB0382 Rapamycin Selectively Increases Circulating Tregcellsand Maintain Remission of Patients with Rheumatoid Arthritis

Rapamycin promotes the expansion of CD4(+) Foxp3(+) regulatory T cells after liver transplantation.

FRI0063 Rapamycin Induces Remission in Patients with Refractory Rheumatoid Arthritis

[Effect of Rapamycin in Inducing Naïve Murine Effector T Cell Convert to Regulatory T Cell].

THU0176 Efficiency and safety of rapamycin combined with low-dose IL-2 treatment compared with methotrexate in patients with rheumatoid arthritis

Rapamycin Immunomodulation Utilizes Time-Dependent Alterations of Lymph Node Architecture, Leukocyte Trafficking, and Gut Microbiome

Rapamycin Inhibition of Eosinophil Differentiation Attenuates Allergic Airway Inflammation in Mice.

The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.

Comparing the Effects of the mTOR Inhibitors Azithromycin and Rapamycin on In Vitro Expanded Regulatory T Cells

Rapamycin Ameliorates Experimental Autoimmune Uveoretinitis By Inhibiting Thl/Th2/Th17 Cells And Upregulating Cd4+Cd25+Foxp3 Regulatory T Cells

Metabolic Disruption Induced by mTOR Signaling Pathway Inhibition in Regulatory T-Cell Expansion for Clinical Application

Rapamycin ameliorates CCl4-induced liver fibrosis in mice through reciprocal regulation of the Th17/Treg cell balance.

The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism

Rapamycin together with TGF-β1, IL-2 and IL-15 induces the generation of functional regulatory γδT cells from human peripheral blood mononuclear cells.

Rapamycin recruits SIRT2 for FKBP12 deacetylation during mTOR activity modulation in innate immunity

Immunomodulation of T Cell-Mediated Alloimmunity by Proximity to Endothelial Cells under the Mammalian Target of Rapamycin Blockade.

Effects of rapamycin on number and activity of endothelial progenitor cells

Rapamycin Directly Activates Lysosomal Mucolipin TRP Channels Independent of Mtor

Rapamycin-resistant effector T-cell therapy